Jensing Liu

Title: Jensing Liu: Innovator in Cancer Therapeutics

Introduction

Jensing Liu is a prominent inventor based in Round Rock, TX (US), known for his significant contributions to the field of cancer therapeutics. With a total of 4 patents to his name, Liu has been at the forefront of developing innovative clinical methods and molecules aimed at treating various forms of cancer.

Latest Patents

Liu's latest patents include groundbreaking work on clinical methods for the use of a PD-L1-binding molecule comprising a Shiga toxin effector. This patent focuses on PD-L1-binding molecules that can selectively kill specific cells, such as PD-L1 positive tumor cells, and deliver therapeutic agents to these cells. The implications of this work are profound, as it offers potential treatments for conditions like non-small cell lung cancer and squamous cell carcinoma of the head and neck.

Another notable patent involves a multivalent CD20-binding molecule that comprises Shiga toxin A subunit effector polypeptides. This invention is designed for the selective killing of specific cell types and serves as a therapeutic option for various diseases, including cancers and immune disorders. These multivalent molecules can also be utilized to deliver agents into CD20-expressing cells, thereby enhancing diagnostic capabilities and treatment monitoring.

Career Highlights

Jensing Liu is currently associated with Molecular Templates, Inc., where he continues to push the boundaries of cancer research and therapeutic development. His work is characterized by a commitment to innovation and a focus on creating effective treatments for patients in need.

Collaborations

Liu collaborates with notable colleagues such as Eric Poma and Erin Willert, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Jensing Liu's contributions to cancer therapeutics through his innovative patents and collaborative efforts highlight his role as a leading inventor in the field. His work not only advances scientific knowledge but also holds the promise of improving patient outcomes in cancer treatment.